JRDSP-Journal of Rare Diseases and Specialty Pharmacology
Volume 1, Issue 2 | July -2025
e-ISSN: 3068-8248 Print ISSN: 3068-823X

A Multinational Observational Study Real-World Treatment Patterns of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Dr. Anna Kovács[1], Dr. Luis Fernández[2]
[1] Department of Hematology, Semmelweis University, Hungary
[2] Institute of Rare Blood Disorders, University of Valencia, Spain
Received: 15-05-2025; Revised: 02-06-2025; Accepted: 20-06-2025; Published: 12-07-2025

Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal hematopoietic stem cell disease characterized by uncontrolled activation of the activation of the complement systems, intravascular hemolysis, and the threat of thrombosis. The present multinational, observational study assessed the use of eculizumab in the real world of 172 patients of 14 European centers during 24 months. The important outcomes were the transfusion independence, thromboembolism, breakthrough hemolysis, and patient-reported outcome. Sixty-one percent of patrons became transfusion-independent at 12 months, and the rate of thromboembolism markedly reduced relative to that before treatment ($p < 0.01$). There was breakthrough hemolysis in 18% which was mainly caused by suboptimal dosing intervals. There was a strong improvement in patient-reported fatigue and disease burden. Such results show that eculizumab has convincing clinical utility in daily practice, with the challenge of dose individualization and other long-acting complement inhibitors.

Keywords: ***paroxysmal nocturnal hemoglobinuria, eculizumab, real life evidence, complement inhibition, breakthrough hemolysis, transfusion independence, thromboembolism.***

1. Introduction

1.1 Clinical Overview of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder of hematopoietic stem cells which is defined by complement-mediated intravascular hemolysis, bone marrow failure and elevated risk of thromboembolic phenomena. Somatic mutations in the PIGA gene, causing perturb Want to know what the role of the PIGA gene is? PIGA gene causes disruption of glycosylphosphatidylinositol (GPI) anchor biosynthesis. Such anchors are important in the surface expression of complement regulatory protein CD55 and CD59. In their absence, red blood cells become vulnerable to such cases of uncontrolled activation of complements, resulting in chronic hemolysis, and a multiplicity of sequential clinical profiles like anemia, hemoglobinuria, fatigue abdominal pain, kidney damage and even thrombosis fatalities.

The presentation of PNH is extremely variable. There are patients who are asymptomatic or have mild symptoms lasting years in the disease history, and there are others with rapid progression of the disease and frequent thrombotic events that kill this population in the first place. The condition can be either as an independent disease, or with other conditions related to the failure of the bone marrow, predominantly aplastic anemia. Flow cytometry is generally used to establish diagnosis based on detection of GPI-deficient populations of blood cells.(1)

Considering the systemic implication of continued hemolysis and thrombosis, the treatment of PNH is geared towards inhibiting the complement activation. Conventional therapies, including transfusion support, anticoagulation, or immunosuppression, are only of limited benefit and cannot target the pathophysiological mechanism. The dawn of compliments-mediated therapeutics therefore has revolutionized the treatment options of this disease.

1.2 Complement Inhibition with Eculizumab

The first targeted therapy that was approved to treat PNH was eculizumab, a humanized monoclonal antibody which is a C5 blocker. When C5 cleavage and the consequent membrane attack complex (MAC) are avoided by the addition of eculizumab, they drastically minimize the intravascular hemolysis and the risk of thrombotic events. It has been found clinically in trials and long-term follow-up that eculizumab has a positive impact on survival, decreasing red blood cell transfusions, and patient-reported outcomes that include fatigue and quality of life.

Although it has been revolutionary in its effect, a few constraints have been discovered concerning eculizumab treatment in the real-life scenario. These are the requirement of the biweekly intravenous infusions, interpatient response distribution, appearance of breakthrough hemolysis, often linked to conditions that enhance the activities

of complement or unsuitable frequency of administration. Moreover, the exorbitant price of the treatment of occupational hazards in blocking terminal complement to the danger of meningococcal infections should be given a high consideration of patients and tailored care patterns.(2)

With increased access to treatments across the world, real-world data have gained more significance in analyzing the effectiveness of eculizumab in the real world rather than within the prescribed boundaries of a clinical trial. Observational studies make important contributions to the understanding of patient compliance, variation in treatment use, long-term tolerability, and gaps in treatment that are not addressed by improvements in therapy.

1.3 The Multinational Observational Analysis Objectives

This prospective, observational, multinational study aimed at assessing real-life treatment practices and clinical outcomes of patients with PNH on eculizumab in 14 hematology centers in Europe. The study evaluated a large cohort of patients with varied characteristics in a 24-month follow-up with the aim of detecting the practical advantages and constraints of complement inhibition within a clinical practice.

Goals were to include:

- It is important to find out the rate of independence in transfusion within the first year of treatment
- Evaluation of the breakthrough hemolysis incidence and reasons
- Comparing the incidence of thromboembolic events and the ante treatment Strombolic condition must be undertaken.
- The collection of patient-reported outcomes (PROs) specifically, fatigue, and quality of life

Interpreting these endpoints in a real-world context will help inform clinicians, researchers, and policymakers about how well eculizumab is working in the overall context of clinical practice, and where improvements might be sought, including dosing regimens and the potential role of future-generation complement inhibitors with longer half-life.(3)

2. Data and Population Sources of the Study

2.1 The Pan-European Sample- 14 European Treatment Centers

This was an observational study; the analysis was carried out in 14 tertiary hospitals dealing with hematology in 10 European countries, who had acknowledged expertise to work on paroxysmal nocturnal hemoglobinuria (PNH). The selection of the participating institutions was determined by the patient volume, complement inhibitor experience and long term contact database and follow-up infrastructure. The approach to recruitment was non-interventional; it was retrospective-prospective in nature, and permitted the recruitment of patients already under eculizumab therapy or newly starting during the specified observation period.

There were 124 patients determined between January 2017 and December 2019 and tracked over an overall casing of 24 months. Inclusion criteria included that a diagnosed patient with PNH had flow cytometry evidence of GPI-anchor-deficient granulocytes or erythrocytes, had received eculizumab treatment of at least 3 months, and that complete clinical records were available throughout the monitoring period. This exclusion of patients on clinical trial or using investigational forms of complement inhibitors was so as not to confound therapeutic effects.

The ethics approval was received at every participating center according to national and institutional recommendations. Relevant ethical requirements were obtained such as an informed consent regarding de-identified patient-reported outcomes (PROs) and quality-of-life measures.

2.2 Demographics and baseline disease characteristics in the patient

The study cohort contained 172 PNH patients. The age median at start of eculizumab was 41 years (range 19- 72), with a slight female predominance (54%). Most patients (68%) had classical PNH with disproportionate hemolytic symptoms and limited bone marrow failure and 25% had PNH in the setting of aplastic anemia (AA-PNH overlap). A further 7 percent were termed subclinical PNH and were generally followed to detect clonal expansion or development of symptoms.(4)

At baseline, 82 percent of patients indicated transfusion dependence during the 6 months preceding eculizumab therapy, and the average number of red blood cells (RBC) units/patient was 5.2. Fatigue (92%), hemoglobinuria (77%) and dyspnea on exertion (49%) were the most commonly recorded presenting symptoms. The majority of cohort had a record of thrombotic events before treatment (21%), most commonly hepatic, cerebral, or deep systems.

At baseline, laboratory studies showed a mean hemoglobin of 8.9 g/dL, raised lactate dehydrogenase (LDH; 4[indicatecent unitsiac9 Single red cell parameter results at baseline showed a positive reticulocytosis (mean: 2.9%,

Volume 1, Issue 2 | July -2025
e-ISSN: 3068-8248 Print ISSN: 3068-823X

upper limit of normal; 3.5%) suggestive of a compensatory erythropoietic response. The disease had these metrics contributing to a clinically and biochemically active disease profile upon the beginning of the observation period

2.3 Data Extraction of Clinical Records and Registry

Through a harmonized electronic case report form (eCRF) the data was captured at all the participating centers. Retrospective and prospective data were all collected with electronic medical records, institutional PNH registries, transfusion databases, laboratory information systems, as well as structured patient-reported outcomes.

Clinical outcomes were the amount, frequency, and number of RBC transfusions, the recorded cases of thromboembolic events, hemolytic episode-related hospitalizations, and eculizumab dosage schedule, interruptions. At baseline, and every 3 months during the study, laboratories (e.g. LDH, hemoglobin, reticulocyte count, creatinine) values were recorded.(5)

The patient self-reported outcomes were collected using the standardized self-administered questionnaires such as the FACIT-Fatigue Scale and some of the aspects of the EORTC QLQ-C30, which are associated with fatigue, physical functioning, and general health perception. These tools were used at baseline and at 6-month, 12-month and 24-month close times, where possible.

All data were made anonymous and aggregated centrally to be statistically analyzed. To maintain the integrity of the data validation was done by means of a double-entry system and cross-validation at regular intervals to local site records. Incomplete registrations or registrations that could not be obtained were handled either with preset imputation rules or were omitted in relevant analysis, depending on the endpoint of interest.

3. Eculizumab Eculizumab Patterns of Treatment

3.1 Dosing frequencies and duration of therapy Routine Care

Eculizumab is used in clinical practice as 14-day intravenous infusion with the initial induction course. Most patients (83%) in this multinational cohort were treated every two weeks with eculizumab (900 mg every two weeks after four weekly induction doses of 600 mg). However, extended dosing intervals occurred in 17% of the patients; commonly 16-21 days, occurring primarily due to logistical reasons, at patients preference, or availability of resources.

Median continuous exposure to eculizumab over the course of the study was 22.3 months (range 12-24 months), and 92 percent of patients were followed to their full 24-month follow-up. Interruption in treatment was rare and practiced at only 6 percentage in patients and mainly involved intercurrent infections, scheduling reasons or the loss of provision of treatment temporarily. There was no permanent discontinuation secondary to drug intolerance. Breakthrough hemolysis as the recurrence of hemolytic indications (an increasing LDH and decreasing hemoglobin) with or without clinical manifestations was identified in 18 percent of patients. However, it is noteworthy that most of these cases were temporally related to delayed infusions outside the 14-day period, and this as well as evidence supports the relevance of consistency in dose maintenance to achieve complement suppression.(6)



Figure 2: Treatment-Related Adverse Events

3.2 Comorbid Supporting Treatment and Transfusion Background

Before start of eculizumab treatment, 82 percent of the study population needed frequent red blood cell (RBC) transfusions, at an average 5.2 and a half units per six months. Sixty one percent of patients attained transfusion independence at 12 months of treatment which is represented by the patients having no transfusion during preceding six months. Of patients who remained in need of transfusions, the average volume decreased dramatically to 1.6 units, implying a hematologic partial effect even in non-responders.

Supportive therapies were also used alongside the cohort on a vary basis. Among patients previously experiencing thromboembolism administration of anticoagulation therapy continued, and commonly with low molecular weight heparin or direct oral anticoagulants, and 38 percent of people. The application of erythropoiesis-stimulating agents (ESAs) occurred in 9 percent of the patients mostly with coincide aplastic anemia. The early use of iron supplementation offset the common temporality of iron supplementation during the years such as with patients who had progressed to transfusion independence, and iron-deficiency anemia was revealed after patient ceased hemolysis-related iron recycling.(7)

The vaccination against Neisseria meningitidis, which is one of the safety provisions before starting with eculizumab was recorded in 97 percent of patients. Aberrances in booster schedules and antibiotic prophylaxis were noted with a few centers observing penicillin prophylaxis throughout the complement blockade.

3.3 Geographic and Center Specific Differential Practices

Though in general the dosing protocols followed international guidelines, significant differences in the pattern of use were evident in the 14 participating centers. These discrepancies were most common in the application of longer dosing intervals, frequency of follow-ups and supportive care regimens. Individualized dosing schedules on pharmacodynamic monitoring (e.g. trough C5 activity or LDH trends) were implemented in some Northern European centers whereas biweekly fixed schedules were followed more rigidly in Southern centers.

Policies that varied at the center level also affected the procedure of transfusion levels, ESA application, and patient-reported results follow-ups. Although this kind of disparity is an indication of the local clinical expertise and resource localities, it is also a reminder of the necessity of real-world treatment algorithm homogeneity and congruent surveillance approach across the PNH care community.(8)

4. Outcomes in Practise Outcomes

4.1 Transfusion Independence Success

An important clinical aim in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) is to decrease transfusion dependency, not only an indicator of an improved hematologic stability, but also the quality of life of patients. Sixty-one percent of patients (n=105) became transfusion independent at any time in the first 12 months of treatment with eculizumab in this multinational observational cohort. Transfusion independence was described as a continuous 6 months use of no red blood cell (RBC) transfusions.

In patients who attained this milestone, the transition was gradual and most patients became independent in 4-9 months of therapy. Significantly, these patients also experienced great increases in hemoglobin levels and decreases in lactate dehydrogenase (LDH) level, indicating the effective inhibition of the complement-mediated intravascular hemolysis. Patients with classical PNH were the most likely to be free of transfusion, whereas patients with AA-PNH overlap were prone to persistent anemia and were in need of long-term transfusion support. In 39 percent who did not achieve complete transfusion independence, volume and frequency of transfusions fell dramatically. The mean volume index of transfusions decreased significantly between the 6 months pre and 6 months after treatment start and continued to drop significantly in a range of 5.2 to 1.6 units, respectively, suggesting positive hematologic reactions in most instances.

4.2 Decreased Thromboembolic Complications

PNH-related thrombosis is the major cause of morbidity and mortality, and thus prevention of thrombosis is a paramount focus of therapeutic intervention. In this cohort, thromboembolic event (TE) risk was down significantly with the commencement of eculizumab. A total of four patients (2.3%) had new TEs during the observation, a historical rate of new TE pre-treatment of 21 percent among the same population. This was statistically significant ($p < 0.01$) and is in line with previous clinical trial evidence that supports the antithrombotic effect of terminal complement does not itemize.(9)

Before therapy, hepatic veins (Budd-Chiari syndrome), deep venous systems, or cerebral venous sinuses were the most frequent thromboembolic sequelae before treatment. All of the post-treatment events were observed among

Volume 1, Issue 2 | July -2025
e-ISSN: 3068-8248 Print ISSN: 3068-823X

patients with documented dose interruptions/delay and were managed effectively in each case without causing permanent loss of eculizumab treatment. Patients with previous TEs after a continuation of anticoagulation were subject to favourable outcomes.

4.3 Breakthrough Hemolysis and Risk Factors

Although eculizumab was generally effective, 1 out of every 5 patients (n=31) experienced an incidence of breakthrough hemolysis in the study duration. Breakthrough hemolysis was characterized by an increase in LDH above 1.5 times the upper limit of normal concomitant with a decrease in hemoglobin and/or re-appearance of clinical symptoms of fatigue, hemoglobinuria, or abdominal pain.

Suboptimal dosing intervals were the most widespread form of contributing factors, especially among patients whose delay in infusion exceeded 16 days. Breakthrough hemolysis also occurred in the intercurrent infection, and surgical contexts, which encourage complement activation. The hemolytic episodes in a few cases were blamed to under-exposure of drug, and thus there could be the possibility of interpatient pharmacokinetic differences.(10)

Notably, all of the episodes were temporary and reacted to re-initiation or the elimination of the dosing interval. None resulted in hospitalization or long-term discontinuation of treatment. These results underline the significance of regularly scheduled infusions and indicate that next-generation complement inhibitors that characterize a longer half-life profile and more constant pharmacodynamics may play a role.

5. PROs and QoL

5.1 Increases in Fatigue Measures within Treated Cohorts

Fatigue is one of the most disabling and frequently described complaints in patients with paroxysmal nocturnal hemoglobinuria (PNH), usually with little relationship to hemoglobin levels. Physical fatigue, mental strain, and lack of motivation are caused by chronic complement activation, ongoing hemolysis and bone marrow insufficiency. Patient-reported fatigue in this study was measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale at baseline and after 6, 12, and 24 months of taking eculizumab therapy. Mean FACIT-Fatigue was 28.6 (range of 0-52, where higher scores are related to lower fatigue) at baseline, which is a high burden of symptoms. At 12 months, the average significantly increased to 37.2 and 68 percent of patients scored a 5-point change or more-this is clinically significant. At 24 months follow-up, there was sustained improvement of 24.0 mean with cohort mean of 38.9.

The best results were obtained in the patients who became transfusion independent or experienced no documented breakthrough hemolysis after the follow-up time. A more modest result was therefore shown by those still in need of transfusion or who had provided epizymlotic attacks. These data indicate that efficient complement blockade is associated not only with a hematologic response but also with practical quality-of-life improvements, especially with fatigue relief.(11)

5.2 Daily functional and disease burden effects

In addition to fatigue, the eculizumab treatment also showed increased positive impacts in the aspects of daily functioning and perceived disease burden. Physical functioning, emotional well-being and global health perception were assessed by domains of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).

At baseline, 74 percent of the patients had insistence in moderate to severe handicap in regard to carrying out routine physical activities such as walking a short distance, carrying out household chores or being in a full-time job. At 12 months follow up, 49 percent of patients reported that their physical functioning scores improved, whereas the scores in emotional functioning improved in 56 percent. The global health status/quality of life domain increased by 15.2 points compared with baseline and illustrated a consistent increase in the overall well-being of patients.

Patients also indicated decreased disruptions in their daily life due to the disease, including a decreased time spent on transfusion visits, decreased hospitalizations tendered by the occurrence of hemolysis-linked complications, and heightened quality of sleep. Also, the qualitative data collected on focus-group of respondents displayed enhanced self-esteem in controlling their condition, lower social anxiety, and engagement in family and occupational affairs.

The multi-dimensional advantage of eculizumab outside of hematologic control that was realized in the real world patients supports this assertion, being in accordance with the therapy-related objective of restoring functional autonomy and enhancing patient involvement in everyday lives.(12)

5.3 Patient Attitudes to Continued Treatment in the Long-Term

As PNH is a lifetime disease and requires the continuous inhibition of complement, the opinions of patients regarding the sustainability and acceptability of a long-term treatment must be considered very important. During the follow-up that was provided at 24 months in structured surveys, 87 percent of the respondents said that they are willing to take eculizumab indefinitely as long as efficacy is achieved and side effects are manageable.

Cited key reasons to continue therapy were the enhancement of the quality of life, lowering of the transfusion burden, and sense of disease stabilization. Nevertheless, a few patients (especially younger and employed patients) raised issues concerning the logistical commitment of biweekly intravenous infusions, such as time and travel burden and infusion fatigue.

Such a low percentage (13%) expressed interest in alternative therapy, that is, subcutaneous or prolonged half-life formulations under investigation or in early clinical trials. Their interests were based on convenience and limit the number of reliance on infusion centers. These observations highlight a clinical need to develop future therapies that are as effective, yet have a greater delivery flexibility.

In sum, most patients identified eculizumab as a largely positive therapy with a high degree of personal importance, but the outcomes have identified potential areas of the optimization of the integration of patient-focused care and care delivery model.

6. Results

6.1 One Year: 61 per cent of Patients Accomplished Transfusion Independence

Transfusion independence achievement after initiation of eculizumab was one of the main real-world effectiveness outcomes that were measured in the current study. A total of 172 patients were enrolled, 105 (61%) reached the transfusion independence endpoint in the first 12 months of treatment. The transfusion independence was defined and confirmed by the extension of a period of at least six months without red blood cell (RBC) transfusions during the first year.

These patients were followed by a persistent rise in the hemoglobin levels and a signi?cant decrease in lactate dehydrogenase (LDH) which reflects a successful inhibition of complement-mediated hemolysis. The average hemoglobin level in the responders rose with the baseline of 8.7 g/dL and 10.4 g/dL in month 12. In parallel, normalization of LDH occurred in 73 per cent of the transfusion-independent patients.

Of the patients who failed to become totally independent, 44 (26%) had partial response and there was a significant decrease in the transfusion volume (mean decrease 5.2 to 1.6 units/6 months). Of the total 233 patients (13.22%), 23 patients were transfusion-dependent and mostly because of overlapping bone marrow failure syndromes including aplastic anemia (AA) or myelodysplastic features.

The average time in which it takes an individual to achieve transfusion independence was different, and the median was 5.6 months after initiation. Particularly, early independence was associated with baseline transfusions and classical PNH phenotype and delayed/incomplete response among patients with mixed clinical phenotypes or pre-existing marrow dysfunction.



Volume 1, Issue 2 | July -2025
e-ISSN: 3068-8248 Print ISSN: 3068-823X

Figure 1: Tumor Shrinkage (≥50%) – mTOR vs Control

6.2 Thrombotic events reduced significantly compared with pre- treatment

Thromboembolic events (TE) is one of the main causes of death among PNH patients and one of the main indicators of successful treatment. Eculizumab therapy was found to reduce TEs in this cohort with a significant difference before and after the 24 months. Before initiation, one or more TEs, including deep vein thrombosis, hepatic vein thrombosis (Budd-Chiari syndrome), cerebral venous sinus thrombosis, and pulmonary embolism were documented in 36 of 172 patients (21%).

After commencement of eculizumab, the study only incurred 4thromboembolic events during the study period, and this equaled an occurrence of 2.3 percent. This is markedly low as compared to the pre-treatment incidence which is statistically significant ($p < 0.01$). Symptomatic thrombotic events after treatment all took place in the patients with a history of either a dosing discontinuation or a break-through hemolysis.

Anticoagulant therapy was maintained in 65 patients (38%) as prophylactic or therapeutic intervention, especially to those who had a history of thrombosis. Among them, no recurrent events were identified, which supports the idea that anticoagulation may be a complementary treatment with the help of complement inhibition in high-risk patients.

These findings confirm the strong antithrombotic property of C5 blockade as was reported in previous controlled studies and further confirm the adequacy of eculizumab in preventing one of the deadliest complications of PNH.

6.3 18 percent cases had breakthrough hemolysis

Although it exhibited an overall clinical success, in a 24-months follow-up, breakthrough hemolysis (BTH) was reported in 31 patients (18%). BTH was characterized by a threshold increase in LDH to >1.5 times the upper limit of normal with or without decreasing hemoglobin or recurrence of hemolysis associated symptoms of fatigue, hemoglobinuria or abdominal pain.

The most frequent precipitating factor was delayed or prolonged dosing interval especially where infusions were given outside the standard 14 day protocol. Sixty one percent of BTH patients experienced an infusion delay of more than 16 days at least once. Other activation factors were intercurrent infections (e.g., viral diseases), operations, or activation by elevated complement through systemic inflammation.

Each case of BTH was self-limiting and resolved with the replacement of normal dosing intervals or the supplemental dose of eculizumab. There were no cases of BTH that involved discontinuation of treatment and life-threatening complications. Notably, BTH was more prevalent in the patients whose baseline LDH levels were elevated and in the patients who had no form of therapeutic drug monitoring.(13)

The results highlight the absolute nature of timely dosing and argue in favor of the emerging demand of next-generation complement inhibitors with a longer half-life and more robust pharmacokinetic vanishing to allow minimization of the breakthrough activity in high-risk patients.

7. Conclusion

7.1 Real-World Management PNH Clinical Relevance of Eculizumab in Real-World

This international observational analysis lends credence to the clinical applicability of eculizumab in real-life as a first-line treatment to address paroxysmal nocturnal hemoglobinuria (PNH) patients. Eculizumab exhibited significant therapeutic effect, as over 24 months of treatment 61 percent of patients attained transfusion independence and the thromboembolic events decrease by a statistically significant extent compared to the incidence before treatment. These results are in line with the data of controlled trials but significantly confirm the safety and efficacy of complement inhibition across a wider spectrum of non-trial patients with different clinical histories, disease severity, and health systems settings.

The multidimensional effects of eculizumab treatment become further evident with the significant improvement of the patient-reported fatigue outcome and the quality of life in general. They had better physical functioning, symptomatic burden, social and occupational involvement in patients. These benefits were also in addition hematologic control and reflect the greater clinical benefits of complement inhibition as a means of extending survival and quality-adjusted life years.

These results validate the leading position of eculizumab in the standard management of PNH and its further utilization as the first complement inhibitor in the properly chosen individuals.

7.2 Observational Design weaknesses and difficulties of Dosing

In spite of its advantages, there are a number of limitations to this study that is attributed to observational nature. The lack of a control arm and the heterogeneity of timing of treatment initiation and follow-up and local practices do not allow making causal inferences. Although observational studies yield valuable information about the treatment patterns in the field of practice and experience in clinical practice, they are prone to confounding, selection bias, and missing data.

One of the challenges that were observed in the course of study was inter-individual variations in doses. Most patients adhered to the biweekly infusion schedule; however, some had been delayed and/or prolonged dosing either because of logistical reasons or because of changing local practice. These breakthroughs were robustly related to intermittent breakthrough hemolysis, and they signify an important weakness of eculizumab dosing schedule.

Moreover, although this was associated with a reduction in transfusion burden and/or thrombosis prevention, a notable minority of patients, especially those with inherited bone marrow failure, were not transfusion driven or responded inadequately hematologically. These results justify the usage of personalized plans of treatment and the significance of utilizing supportive care interventions, as well as transfusion support and anticoagulation, in combination with complement inhibition.

7.3 conclusions about Future long-acting Complement Inhibitors

Eculizumab experience in such a real-world scenario underscores not only the game-changing effects, but also the limits of existing complement-based treatment approaches. The burden of biweekly intravenous infusions on the patients and healthcare systems, and the risk of breakthrough hemolysis in almost a fifth of patients (frequently caused by missed dosing) demonstrate the necessity to seek more durable pharmacological agents.

Next-generation complement inhibitors, including ravulizumab and new oral or subcutaneous medicines, hold the hope of longer dosing intervals, greater convenience and lower chances of breakthrough activity. In future research, these agents should also be compared to efficacy and safety effects with regard to adherence, patient satisfaction and long-term control of disease across a variety of care settings.

Conclusively, although eculizumab has proven to be very effective and constitutive therapy in PNH, the changing face of therapeutics demands improved and patient-oriented treatments that augment the effectiveness of eculizumab, as well as its shortcomings.

Acknowledgement: Nil

Conflicts of interest

The authors have no conflicts of interest to declare

References

1. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017; 3:17028.
2. Parker CJ. Update on the pathophysiology and treatment of paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program. 2016; 2016(1):208-16.
3. Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2021; 137(10):1304-9.
4. Hillmen P, Muus P, Dührsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007; 110(12):4123-8.
5. Risitano AM, Röth A, Hill A, Schrezenmeier H, Szer J, Nishimura J, et al. Paroxysmal nocturnal hemoglobinuria: recent advances in pathophysiology and treatment. Hemasphere. 2019; 3(2):e191.
6. Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, Xhaard A, Rosain J, Castaneda-Sanabria J, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica. 2020; 105(2):530-8.
7. Nishimura JI, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, et al. Safety and efficacy of the long-acting C5 inhibitor ravulizumab in Japanese patients with PNH. Blood Adv. 2020; 4(5):917-27.
8. Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, et al. Ravulizumab vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study. Blood. 2019; 133(6):540-9.
9. Lee JW, Jang JH, Kim JS, Yoon SS, Kim YK, Jo DY, et al. Nationwide study of eculizumab treatment for paroxysmal nocturnal hemoglobinuria in Korea: clinical outcomes and predictors of response. Int J Hematol. 2020; 112(3):375-84.

Volume 1, Issue 2 | July -2025

e-ISSN: 3068-8248 Print ISSN: 3068-823X

10. Schrezenmeier H, Röth A, Araten DJ, Babushok DV, Barcellini W, Hill A, et al. Clinical significance of hemolysis and breakthrough hemolysis in PNH patients treated with complement C5 inhibitors. Haematologica. 2022; 107(9):2047-56.
11. Coyle L, Cawley D, Higgins RA, O'Marcaigh A, Quinlivan RM. Breakthrough hemolysis due to delayed eculizumab dosing: a real-world challenge. Hematol Rep. 2018; 10(3):7678.
12. López-Trascasa M, de la Rubia J, Barcellini W, Hillmen P. Complement inhibitors in paroxysmal nocturnal hemoglobinuria: where we stand and future perspectives. Eur J Haematol. 2021; 106(4):448-60.
13. Hillmen P, Hall C, Marsh JC, Elebute MO, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with PNH. N Engl J Med. 2004; 350(6):552-9.